Evidence map›Paper›PMID 25056968›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Surface expression of the hRSV nucleoprotein impairs immunological synapse formation with T cells.

Pablo F Céspedes, Susan M Bueno, Bruno A Ramírez, Roberto S Gomez, Sebastián A Riquelme, Christian E Palavecino, Juan Pablo Mackern-Oberti, Jorge E Mora, David Depoil, Catarina Sacristán and 6 more

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03213405 (A Double Blind, Controlled by Conventional BCG, Dose-escalation Phase I Study, to Evaluate Safety, Tolerability and Immunogenicity of a Mycobacterium Bovis BCG), which is not on this map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03213405 phase1completednot on this mapstarted 2017, after this paper: background citation

A Double Blind, Controlled by Conventional BCG, Dose-escalation Phase I Study, to Evaluate Safety, Tolerability and Immunogenicity of a Mycobacterium Bovis BCG (Bacillus Calmette-Guérin) Vaccine, 1331 Danish Strain, Live Attenuated and Recombinant for the Expression of Human Respiratory Syncytial Virus Nucleoprotein (N) in Healthy Males Within 18 and 50 Years of Age

TypeinterventionalSponsorPontificia Universidad Catolica de ChileRan2017 to 2018Enrolled24ConditionsRespiratory Syncytial Virus InfectionsArmsrBCG-N-hRSV 1/100, rBCG-N-hRSV 1/10, rBCG-N-hRSV full dose, Conventional BCG full dose
3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 76 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Cell surface nucleocapsid protein expression: A betacoronavirus immunomodulatory strategy.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 4 countries.

Pablo F CéspedesMillennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, and.
Susan M BuenoMillennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, and.
Bruno A RamírezMillennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, and.
Roberto S GomezMillennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, andInstitut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1064, F44093 Nantes, France;
Sebastián A RiquelmeMillennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, andInstitut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1064, F44093 Nantes, France;
Christian E PalavecinoMillennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, and.
Juan Pablo Mackern-ObertiMillennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, and.
Jorge E MoraMillennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, and.
David DepoilHelen and Martin Kimmel Center for Biology and Medicine, Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, NY 10016;Kennedy Institute of Rheumatology, University of Oxford, Headington, Oxon OX3 7FY, United Kingdom; and.
Catarina SacristánHelen and Martin Kimmel Center for Biology and Medicine, Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, NY 10016;
Michael CammerHelen and Martin Kimmel Center for Biology and Medicine, Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, NY 10016;
Alison CreneguyInstitut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1064, F44093 Nantes, France;
Tuan H NguyenInstitut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1064, F44093 Nantes, France;
Claudia A RiedelMillennium Institute on Immunology and Immunotherapy, Departamento de Ciencias Biológicas, Facultad de Ciencias Biológicas y Facultad de Medicina, Universidad Andrés Bello, Santiago 8370146, Chile.
Michael L DustinHelen and Martin Kimmel Center for Biology and Medicine, Skirball Institute of Biomolecular Medicine, New York University School of Medicine, New York, NY 10016;Kennedy Institute of Rheumatology, University of Oxford, Headington, Oxon OX3 7FY, United Kingdom; and.
Alexis M KalergisMillennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, andInstitut National de la Santé et de la Recherche Médicale, Unité Mixte de Recherche 1064, F44093 Nantes, France;Departamento de Reumatología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago 8331010, Chile; akalergis@bio.puc.cl.
Millennium Institute on Immunology and Immunotherapy · CLNew York University · USPontificia Universidad Católica de Chile · CLInserm · FR

Funding

Targeting the PD-1 signaling pathway to rescue HIV T cell dysfunctionP01AI080192 · NIAID · EMORY UNIVERSITY · PI AHMED, RAFI · 2008 to 2012
$12.6M
Requirement for Sensitive T Cell Response to AntigenR37AI043542 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DUSTIN, MICHAEL LORAN · 2007 to 2016
$3.6M
REQUIREMENT FOR SENSITIVE T CELL RESPONSE TO ANTIGENR01AI043542 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DUSTIN, MICHAEL L · 1999 to 2005
$1.5M
NIAID NIH HHS AI043542NIAID NIH HHS AI080192NIAID NIH HHS P01 AI080192NIAID NIH HHS R01 AI043542NIAID NIH HHS R37 AI043542Wellcome Trust
6 · The paper itself

Abstract

Human respiratory syncytial virus (hRSV) is the leading cause of bronchiolitis and pneumonia in young children worldwide. The recurrent hRSV outbreaks and reinfections are the cause of a significant public health burden and associate with an inefficient antiviral immunity, even after disease resolution. Although several mouse- and human cell-based studies have shown that hRSV infection prevents naïve T-cell activation by antigen-presenting cells, the mechanism underlying such inhibition remains unknown. Here, we show that the hRSV nucleoprotein (N) could be at least partially responsible for inhibiting T-cell activation during infection by this virus. Early after infection, the N protein was expressed on the surface of epithelial and dendritic cells, after interacting with trans-Golgi and lysosomal compartments. Further, experiments on supported lipid bilayers loaded with peptide-MHC (pMHC) complexes showed that surface-anchored N protein prevented immunological synapse assembly by naive CD4(+) T cells and, to a lesser extent, by antigen-experienced T-cell blasts. Synapse assembly inhibition was in part due to reduced T-cell receptor (TCR) signaling and pMHC clustering at the T-cell-bilayer interface, suggesting that N protein interferes with pMHC-TCR interactions. Moreover, N protein colocalized with the TCR independently of pMHC, consistent with a possible interaction with TCR complex components. Based on these data, we conclude that hRSV N protein expression at the surface of infected cells inhibits T-cell activation. Our study defines this protein as a major virulence factor that contributes to impairing acquired immunity and enhances susceptibility to reinfection by hRSV.

Indexed as

AnimalsBrefeldin ACD4-Positive T-LymphocytesCell CommunicationCell LineCell MembraneDendritic CellsGolgi ApparatusHistocompatibility AntigensHumansImmunological SynapsesLipid BilayersLymphocyte ActivationMiceMice, Inbred C57BLNucleoproteinsBrefeldin AHistocompatibility AntigensLipid BilayersNucleoproteinsPeptidesReceptors, Antigen, T-CellViral ProteinscSMACnucleocapsid proteinpSMACT lymphocyte priming

Identifiers

PMID25056968
PMCPMC4128097
OpenAlexW1966142422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.